Does Humana Cover Finasteride? Formulary Tiers, Prior Auth, and Appeals Explained

What Is Finasteride and Why Does the Indication Matter for Coverage?

Finasteride is a 5-alpha-reductase type II inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT). The FDA approved the 5 mg tablet (Proscar) for benign prostatic hyperplasia in 1992 and the 1 mg tablet (Propecia) for androgenetic alopecia in men in 1997 [1]. That distinction matters because insurers, including Humana, apply separate coverage logic to each indication. BPH is a recognized medical condition covered under standard pharmacy benefits; androgenetic alopecia is often classified as cosmetic, triggering exclusions that do not apply to BPH [2].

Finasteride 1 mg reduces scalp DHT by roughly 60% and serum DHT by approximately 70% [3]. In the key Kaufman et al. trial (N=1,553), men treated with finasteride 1 mg daily showed a mean 48% increase in hair count versus a 14% decrease in the placebo group at 24 months (P<0.001) [4]. That trial underpins every coverage-medical-necessity argument for the hair-loss indication but does not change the cosmetic-exclusion problem on Medicare plans.

For BPH, the PLESS trial (N=3,040 to 4 years) found finasteride 5 mg reduced prostate volume by 18%, lowered the risk of acute urinary retention by 57%, and reduced the need for BPH-related surgery by 55% versus placebo [5]. These outcomes place finasteride squarely within standard-of-care BPH treatment per the American Urological Association 2023 guideline [6].

How Humana Structures Its Formulary for Generic Drugs

Humana uses a five-tier formulary on most commercial and employer-sponsored plans, and a similar structure on its Medicare Advantage Prescription Drug (MAPD) plans [7]. Generic drugs with long market histories typically land on Tier 1 (preferred generic) or Tier 2 (non-preferred generic). Finasteride went generic in 2006 for the 5 mg strength and in 2014 for the 1 mg strength, so both are firmly established generics [8].

On commercial plans, Tier 1 cost-sharing usually means a $0 to $10 copay per 30-day supply at a preferred pharmacy. Tier 2 copays typically run $15 to $40, depending on the specific plan design [9]. The exact tier for your plan appears in the plan's Evidence of Coverage (EOC) document or the online drug-lookup tool at Humana.com. Because Humana sells dozens of distinct plan SKUs across states, no single tier assignment applies universally.

On Medicare Advantage plans, CMS Part D rules prohibit coverage of drugs used for cosmetic purposes [10]. Androgenetic alopecia falls under that cosmetic exclusion at the federal level. A Humana MAPD plan therefore cannot legally cover finasteride 1 mg for hair loss even if the plan wanted to do so. The 5 mg BPH indication sits in a different category: CMS allows coverage for BPH treatment, so Humana MAPD plans may list finasteride 5 mg on their Part D formulary, often at Tier 1 or Tier 2 [11].

Does Humana Require Prior Authorization for Finasteride?

On most Humana commercial plans, generic finasteride for BPH requires no prior authorization (PA). The drug has decades of safety data, generic pricing keeps it low-cost, and BPH is straightforwardly diagnosed by symptom score and prostate examination [12]. PA requirements are more common for brand-name Proscar or Propecia, which carry list prices near $85 per month, but those are rarely prescribed now that generics are available [13].

For androgenetic alopecia on commercial plans, some Humana policies do require PA or even classify the drug as a cosmetic-exclusion item. The PA criteria typically ask for documentation of a confirmed diagnosis (ideally with a dermatologist or urologist note), confirmation that the prescriber is using the on-label 1 mg dose, and occasionally a statement that the patient has not responded to minoxidil [14].

On Medicare Advantage plans, the situation shifts considerably. Because the cosmetic exclusion blocks coverage of finasteride for hair loss outright, a PA request will be denied on grounds of non-coverage rather than medical necessity. For finasteride 5 mg for BPH on an MAPD plan, PA may be required depending on the specific plan. Humana's MAPD PA criteria for BPH drugs commonly ask for an AUA Symptom Score of 8 or higher and documentation that watchful waiting alone is no longer appropriate [15]. The 2023 AUA BPH guideline states: "Medical therapy is recommended for patients with bothersome LUTS/BPH who have failed or declined watchful waiting" [6], which aligns with Humana's typical documentation threshold.

Step Therapy Requirements on Humana Plans

Step therapy (also called fail-first) means the plan requires a trial of a less expensive or preferred drug before it will approve the target drug. For BPH, some Humana commercial and MAPD plans require a documented trial of an alpha-1-adrenergic antagonist (tamsulosin, alfuzosin, or silodosin) before approving a 5-alpha-reductase inhibitor such as finasteride [16]. Tamsulosin generic costs under $5 per month, which is the insurer's rationale: try the cheapest option first.

This step is clinically reasonable for patients with predominantly obstructive symptoms and a smaller prostate (under 30 mL), because alpha-blockers work faster and are guideline-recommended for that profile [17]. For patients with prostate volumes above 40 mL or PSA above 1.5 ng/mL, finasteride (or dutasteride) offers disease-modification advantages that alpha-blockers do not, and the AUA guideline explicitly supports 5-alpha-reductase inhibitor use in that population [6]. A letter from the treating urologist citing prostate volume and PSA can override step therapy in those cases.

Step therapy for finasteride 1 mg on commercial hair-loss coverage is less formalized. When PA is required, some plans ask for evidence of a minoxidil trial (typically 4 to 6 months at 5% topical solution) before approving finasteride. That step can be waived if the prescriber documents a contraindication to minoxidil or patient-specific clinical factors favoring finasteride as first-line therapy [18].

HealthRX Step-Therapy Override Decision Framework for Finasteride

Use this framework before submitting a PA or step-therapy override request to Humana:

1. Identify the indication: BPH (5 mg) or androgenetic alopecia (1 mg).
2. For BPH: document prostate volume (ultrasound or MRI), PSA level, AUA Symptom Score, and any prior alpha-blocker trial with dates and outcome.
3. For hair loss on commercial plans: document duration of hair loss, photographic baseline, any prior minoxidil trial, and why finasteride is clinically preferred.
4. For hair loss on Medicare Advantage: do not file a PA for the 1 mg hair-loss indication. The cosmetic exclusion is statutory and will be denied regardless of documentation. Proceed directly to cash-pay or GoodRx pricing.
5. Attach the AUA 2023 guideline citation [6] and the relevant clinical trial citation [4] or [5] to the PA letter.
6. Request peer-to-peer review with a Humana medical director within 72 hours of a PA denial whenever clinical urgency applies.

What Finasteride Costs Without Insurance at Humana-Affiliated Pharmacies

Generic finasteride is among the least expensive prescription drugs in the United States regardless of insurance status. At pharmacies in Humana's preferred network (including Walmart, Walgreens, Kroger, and Humana Pharmacy mail-order), GoodRx and RxSaver prices for finasteride 1 mg (90-day supply) range from approximately $30 to $60, and finasteride 5 mg (90-day supply) often costs $20 to $45 [19]. Splitting 5 mg tablets is pharmacist-approved for patients whose prescriber specifically orders it for hair-loss use at lower doses, though this is an off-label practice and should be done only under clinical guidance [20].

For Medicare beneficiaries whose MAPD plan excludes finasteride for hair loss, cash pay is effectively the only route. The brand Propecia list price of approximately $85 per month is irrelevant in practice because the generic is bioequivalent and dramatically cheaper [21]. The FDA's Office of Generic Drugs confirms that approved generic finasteride products meet the same bioequivalence standards as the reference listed drug [1].

How to Appeal a Humana Denial of Finasteride

Humana denials for finasteride follow different appeal tracks depending on the plan type. Understanding which track applies saves time.

Commercial plan denials. The first step is an internal appeal filed within 180 days of the denial notice. Humana must respond to urgent appeals within 72 hours and standard appeals within 30 days [22]. If the internal appeal is denied, the member may request an independent external review through a state-certified Independent Review Organization (IRO). The IRO's decision is binding on Humana in most states [23].

Medicare Advantage plan denials. CMS mandates a specific five-level appeal process. Level 1 is a redetermination by Humana (7 calendar days for standard Part D). Level 2 is a reconsideration by a Qualified Independent Contractor (QIC), currently MAXIMUS Federal Services for Part D [24]. Level 3 is an Administrative Law Judge (ALJ) hearing (requires a disputed amount of at least $180 in 2025). Levels 4 and 5 are Medicare Appeals Council and Federal District Court, respectively [25].

For a finasteride 1 mg denial on Medicare Advantage citing the cosmetic exclusion, escalating beyond Level 2 is rarely productive unless the prescriber argues the drug is being used for a non-cosmetic indication (for example, documented androgenetic alopecia with documented psychological comorbidity). The CMS Medicare Prescription Drug Benefit Manual, Chapter 6, states: "Coverage excludes drugs when used for cosmetic purposes or hair growth" [10]. That statutory language makes most MAPD finasteride-for-hair-loss appeals unsuccessful past Level 2.

For finasteride 5 mg BPH denials on Medicare Advantage, an appeal grounded in AUA guideline compliance and documented symptom severity has a reasonable chance of success at Level 1 or Level 2, particularly when the denial was based on missing documentation rather than a formulary exclusion [15].

Practical documentation checklist for any Humana finasteride appeal:

• Copy of the denial letter with reason code
• Office notes from the prescribing physician with ICD-10 diagnosis code (L64.0 for androgenic alopecia; N40.1 for BPH with LUTS)
• Lab values: PSA, testosterone (if relevant), and any prior drug-trial records
• Letter of medical necessity citing the Kaufman et al. 1998 trial [4] (for hair loss) or PLESS trial [5] (for BPH)
• AUA 2023 guideline summary statement [6]
• Photographic documentation for hair-loss cases

Filing the appeal with complete documentation at Level 1 reduces the probability of needing to escalate. A 2022 HHS Office of Inspector General report found that Medicare Advantage plans denied 13% of prior authorization requests for Part D drugs, and approximately 75% of appealed denials were eventually overturned when supporting documentation was submitted [26].

Manufacturer Savings Cards and Patient Assistance Programs

Merck, the manufacturer of brand Propecia and Proscar, has historically offered savings cards for commercially insured patients. These cards cannot be used with any federal health program, including Medicare, Medicaid, or TRICARE, per federal anti-kickback regulations [27]. For commercially insured Humana members, a manufacturer copay card may reduce out-of-pocket costs to near zero, but the plan's deductible accumulator rules may prevent the card payments from counting toward the annual deductible [28].

For uninsured or underinsured patients, the Merck Patient Assistance Program (Merck Helps) provides brand-name finasteride at no cost to qualifying patients with household income at or below 600% of the federal poverty level [29]. Generic finasteride is not covered under this program; however, the generic cash price is already low enough that assistance programs are rarely necessary for the generic.

NeedyMeds and RxAssist maintain updated databases of patient assistance programs for finasteride and can be cross-referenced with current Humana coverage decisions [30].

Checking Your Specific Humana Plan's Current Formulary

Formularies change every January 1 under CMS annual plan bid rules, and Humana may update them mid-year for newly approved drugs or pricing changes [11]. The single most reliable method for confirming finasteride coverage is to use the drug-lookup tool on Humana.com, enter your plan ID (found on your insurance card), and search for "finasteride" by both strength (1 mg and 5 mg) and by generic name. The tool will display the current tier, any PA requirement, any step-therapy requirement, and the estimated cost-sharing at your preferred pharmacy.

Alternatively, call the Humana Member Services number on the back of your card and ask specifically: (1) Is finasteride [dose] covered under my plan? (2) What tier is it? (3) Is prior authorization required? (4) Is step therapy required? Document the representative's name, date, and reference number for the call. That record is useful if a pharmacy claim is later rejected and you need to dispute the denial.

Your prescriber's office can also submit a coverage verification (also called a benefit investigation) on your behalf before the prescription is sent to the pharmacy, avoiding an unexpected rejection at the point of sale [31].

Clinical Efficacy Summary: What the Evidence Shows

Finasteride's efficacy data are well-established across both indications. For androgenetic alopecia, the Kaufman et al. trial (N=1,553 to 2 years) showed a statistically significant 48% increase in total hair count in the finasteride group versus a 14% decline in the placebo group (P<0.001) [4]. Investigator assessments rated 65% of finasteride-treated patients as improved versus 37% in the placebo group [4]. A 5-year open-label extension confirmed maintained efficacy with continuous daily use [32].

For BPH, the PLESS trial (N=3,040 to 4 years) demonstrated an 18% reduction in prostate volume, a 57% reduction in acute urinary retention risk, and a 55% reduction in BPH-related surgical intervention versus placebo [5]. The Medical Therapy of Prostatic Symptoms (MTOPS) trial (N=3,047, mean 4.5 years) subsequently showed that combining finasteride with doxazosin reduced the risk of overall clinical progression by 67% versus placebo, compared with 39% for doxazosin alone and 34% for finasteride alone [33]. That combination-therapy evidence is relevant when arguing for finasteride coverage in patients already on an alpha-blocker, directly countering a step-therapy denial that assumes alpha-blockers are sufficient.

Finasteride 5 mg also reduces PSA by approximately 50% after 6 months of treatment [34]. Clinicians and Humana medical reviewers should note this when evaluating PSA trends in men on finasteride; a PSA that fails to halve after 6 months warrants prostate cancer evaluation per the AUA guideline [6].

Sexual side effects (decreased libido, erectile dysfunction, ejaculatory disorder) occur in 3.8% of finasteride-treated patients versus 2.1% in placebo groups in controlled trials [35]. Post-marketing reports have described persistent sexual dysfunction in a small subset of patients after discontinuation, a syndrome sometimes called post-finasteride syndrome; the FDA updated the Propecia label in 2012 to reflect this risk [1]. These documented risks are relevant to any shared decision-making conversation and do not affect the insurance-coverage analysis directly, but they are part of the complete clinical picture your prescriber should discuss before initiating therapy.